<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02696564</url>
  </required_header>
  <id_info>
    <org_study_id>U01HL128951</org_study_id>
    <nct_id>NCT02696564</nct_id>
  </id_info>
  <brief_title>Losartan Effects on Emphysema Progression</brief_title>
  <acronym>LEEP</acronym>
  <official_title>Losartan Effects on Emphysema Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, parallel, placebo controlled trial to evaluate the effect of 100mg/day losartan&#xD;
      on the progression of emphysema as measured by quantitative HRCT compared to placebo&#xD;
&#xD;
      .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a trial designed to test if a treatment, losartan, may decrease the progression of&#xD;
      Chronic Obstructive Pulmonary Disease (COPD). Losartan is an angiotensin receptor blocking&#xD;
      agent, commonly used as an antihypertensive agent, which has been shown to alter cardiac&#xD;
      remodeling after myocardial infarction and renovascular remodeling in diabetes-mellitus. In&#xD;
      this trial participants with mild to severe COPD, with Computed Tomography (CT) evidence of&#xD;
      emphysema (5-35% of voxels with &lt; -950 Hounsfield Units), will be randomly assigned to&#xD;
      receive 100mg/day of losartan or placebo for 48 weeks. The primary outcome measure will be&#xD;
      the rate of progression of emphysema, quantified as the percent of lung voxels with a density&#xD;
      less than -950 HU as measured by High Resolution CT (HRCT, from baseline to 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2017</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in mean pct950</measure>
    <time_frame>48 weeks</time_frame>
    <description>change in percentage of voxels with density less than -950 Hounsfield Units</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At randomization participants will start with a dose of 50mg (one capsule) once a day for 2 weeks. If this dose is well tolerated and systolic BP is &gt;90 mm Hg and diastolic BP is &gt; 60 mm Hg, the dose will be increased to 100 mg (2 capsules) once a day for the remaining 46 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At randomization participants will start with a dose of one capsule (inactive) once a day for 2 weeks. After two weeks, if systolic BP is &gt;90 mm Hg and diastolic BP is &gt; 60 mm Hg, the dose will be increased to 2 capsules once a day for the remaining 46 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one capsule per day for two weeks, followed by two capsules per day for 46 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Mild to severe COPD: Ratio of forced expiratory volume in 1 second (FEV1)/forced vital&#xD;
             capacity (FVC) less than or equal to 0.70, FEV1 20-80% of predicted&#xD;
&#xD;
          -  Current or former smoker&#xD;
&#xD;
          -  HRCT scan with 5-35% of voxels with density less than -950 Hounsfield Units (HU)&#xD;
&#xD;
          -  Ability to understand and willingness to sign consent documents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current therapy with angiotensin converting enzyme (ACE) inhibitor or angiotensin&#xD;
             receptor blocker (ARB)&#xD;
&#xD;
          -  Known intolerance to ACE inhibitor or ARB&#xD;
&#xD;
          -  History of angioedema&#xD;
&#xD;
          -  Conventional indication for ACE inhibitor or ARB (e.g., history of myocardial&#xD;
             infarction, known cardiomyopathy)&#xD;
&#xD;
          -  Renal insufficiency (GFR &lt;30 mL/min by Cockcroft-Gault calculation)&#xD;
&#xD;
          -  Current regular use of NSAIDs defined as daily use 5 or more days of the week for more&#xD;
             than one month&#xD;
&#xD;
          -  Potassium supplementation or serum potassium level of 5.0 milliequivalents (mEq)/dL or&#xD;
             higher at V1&#xD;
&#xD;
          -  Current use of a potassium sparing diuretic&#xD;
&#xD;
          -  COPD exacerbation requiring treatment within 6 weeks at V1&#xD;
&#xD;
          -  Chronic systemic corticosteroid use of more than 10mg/day of prednisone&#xD;
&#xD;
          -  Resting SpO2 &lt;89% on 2 L nasal cannula continuous flow; unless at altitude &gt; 4,000&#xD;
             feet, then resting oxygen saturation (SpO2) &lt;89% on 4 L N C continuous flow&#xD;
&#xD;
          -  Untreated arterial hypertension (systolic blood pressure greater than140 mm Hg,&#xD;
             diastolic blood pressure greater than 90 mm Hg)&#xD;
&#xD;
          -  Blood pressure less than 90 mm Hg systolic or 60 mm Hg diastolic while standing or&#xD;
             sitting&#xD;
&#xD;
          -  Known unilateral or bilateral renal artery stenosis higher than 70%&#xD;
&#xD;
          -  Previous lung resection surgery&#xD;
&#xD;
          -  Evidence of interstitial, occupational or chronic infectious lung disease&#xD;
&#xD;
          -  Changes to chest that preclude adequate HRCT imaging (e.g. Metallic objects in the&#xD;
             chest such as shrapnel or pacemaker leads)&#xD;
&#xD;
          -  For women of child bearing potential, positive pregnancy test or unwillingness to use&#xD;
             two methods of birth control or abstinence for the duration of the study&#xD;
&#xD;
          -  Major chronic illnesses which in the judgment of the study physician would interfere&#xD;
             with participation in the study e.g. including but not limited to: cardiac, renal,&#xD;
             hepatic (LFTs more than 2.5x normal upper limit), neurological, psychiatric, endocrine&#xD;
             or neoplastic diseases, uncontrolled diabetes, uncontrolled HIV infection or other&#xD;
             immune system disorder, hyperthyroidism, seizure disorders, non-skin cancer, rheumatic&#xD;
             diseases&#xD;
&#xD;
          -  Failure to keep screening appointments or other indicators of non-adherence&#xD;
&#xD;
          -  Inability to be contacted by telephone&#xD;
&#xD;
          -  Intention to leave area within 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Wise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janet Holbrook, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Health Network</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospitals</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Hospital and Health Care Center, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Asthma Clinical Research Center - Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai National Jewish Health Respiratory Institute; Icahn School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Lung Center at The University of Vermont</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Northwest Airways - VA Puget Sound Healthcare System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2016</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>emphysema</keyword>
  <keyword>HRCT</keyword>
  <keyword>losartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Emphysema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

